Life Sciences

  • January 30, 2025

    Consumers Want L'Oréal Acne Products Suits In Hawaii

    Plaintiffs suing L'Oréal for selling acne products that could break down into the carcinogen benzene took a second stab at consolidating their lawsuits, asking the U.S. Judicial Panel on Multidistrict Litigation on Thursday to join the suits in Hawaii.

  • January 30, 2025

    Former Pharma Exec Gets 2 Months For Insider Trading

    A former Ipsen Pharmaceuticals executive who pled guilty to insider trading last fall was sentenced to two months in prison Thursday, the U.S. Attorney's Office in Boston has announced.

  • January 30, 2025

    DOJ Calls UnitedHealth Dismissal Bid A Discovery 'End Run'

    The U.S. Department of Justice assailed UnitedHealth Group on Wednesday for "masquerading" a "premature" discovery bid as a motion to dismiss the government's Maryland federal court lawsuit challenging the $3.3 billion purchase of home health and hospice giant Amedisys Inc.

  • January 30, 2025

    Samsung Gets PTAB To Review 2 Smart Ring Patents

    The Patent Trial and Appeal Board has agreed to hear Samsung's challenge to a pair of patents owned by a company that makes smart rings, finding there was a reasonable chance the electronics giant could potentially prevail in the fight.

  • January 30, 2025

    RFK Blasts Industry 'Puppets' Amid HHS Nomination Fight

    Robert F. Kennedy Jr. said Thursday that federal scientific panels are rife with conflicts of interest that have turned them into "sock puppets" for industry, as he faced a second day of intense questioning on Capitol Hill and sought support for his nomination as secretary of health and human services.

  • January 30, 2025

    NC Biz Court Bulletin: Sanctions Miss, Philip Morris Refund

    In the second half of January, the North Carolina Business Court tussled with sanctions against a biogas company, heard claims an insurer tried to deliberately embarrass Cadwalader Wickersham & Taft LLP and ordered an $11 million tax refund for Philip Morris.

  • January 30, 2025

    Orrick Adds Head Of Antitrust Litigation From Weil

    Orrick Herrington & Sutcliffe LLP has hired Eric Hochstadt from Weil Gotshal & Manges LLP as the firm's new head of antitrust litigation and a member of its management committee, the firm announced Thursday.

  • January 30, 2025

    Rumors Fly As Trump Seeks Deal To Keep TikTok Alive

    President Donald Trump seems to be getting exactly the "bidding war" he wanted as multiple entities fight for a role in keeping TikTok available in the U.S. Here, Law360 provides a rundown of the latest rumors and developments in the TikTok saga, along with other notable rumors from the past week.

  • January 30, 2025

    Cooley, Latham Steer Beta Bionics' Upsized $204M IPO

    Shares of insulin-delivery device maker Beta Bionics Inc. soared in debut trading Thursday after it priced an upsized, $204 million initial public offering at the top of its increased range, represented by Cooley LLP and underwriters' counsel Latham & Watkins LLP.

  • January 29, 2025

    Albertsons Must Face County's Opioid Nuisance Claims

    Albertsons Cos. Inc. can't escape a Texas county's public nuisance claims stemming from opioid sales at the grocery giant's in-store pharmacies, an Ohio federal judge ruled Tuesday, saying there's a "common law duty of care" for pharmacies not to expose the county to a "reasonably foreseeable" risk of harm.

  • January 29, 2025

    Fed. Circ. Affirms Delaying Biosimilars For Regeneron's Eylea

    A West Virginia federal judge has the power to oversee patent infringement litigation against drugmakers from South Korea and Germany and stop them from launching biosimilar versions of Regeneron's blockbuster eye disease treatment Eylea, the Federal Circuit said Wednesday.

  • January 29, 2025

    BI Ignored 'Red Flag After Red Flag' On Zantac, Jury Hears

    Counsel for two men retrying their cancer case against Boehringer Ingelheim told an Illinois state court jury Wednesday that the drugmaker stuck its head in the sand and ignored warning signs that taking its over-the-counter Zantac could lead to cancer development.

  • January 29, 2025

    Court Garbled Pharma Owner's Fraud Charges, 6th Circ. Told

    An Ohio district court misrepresented healthcare fraud charges against a pharmaceutical salesman to a jury, his attorney argued Wednesday before the Sixth Circuit, calling for the court to overturn his 2023 conviction and subsequent restitution order to pay $7 million to the IRS.

  • January 29, 2025

    Labcorp Can't Flip Patent Board Loss At Fed. Circ.

    Labcorp had no luck Wednesday trying to convince Federal Circuit judges to overturn a patent board decision that refused to invalidate a host of claims in a patent covering a way of detecting genetic disorders.

  • January 29, 2025

    Farmers' Antitrust Claims Trimmed In Pesticides Case

    A North Carolina federal court has cut one set of federal antitrust claims from a suit brought by farmers accusing major pesticide manufacturers Syngenta AG and Corteva Inc. of blocking competition but allowed a slew of other claims to proceed.

  • January 29, 2025

    Full Fed. Circ. Won't Allow MSN To Launch Generic Entresto

    The Federal Circuit is standing by its decision to bar MSN Pharmaceuticals from launching a generic version of Novartis' bestseller, the cardiovascular drug Entresto, as Novartis tries to persuade the court that it deserves an injunction through July. 

  • January 29, 2025

    Chinese Co. Execs Convicted Over Fentanyl Chemical Imports

    Two former executives of a Chinese chemical company were convicted Wednesday of charges related to a purported scheme to import fentanyl precursor chemicals in order to manufacture large quantities of the drug, as well as laundering funds.

  • January 29, 2025

    9th Circ. Affirms Ax Of Patent Atty's Allergan FCA Fight

    A Ninth Circuit panel on Wednesday affirmed the dismissal of a patent attorney's False Claims Act lawsuit alleging Allergan and Adamas Pharma fraudulently obtained patents to block generic competition for two Alzheimer's drugs, finding the information he disclosed was already publicly available and so his FCA claims are barred.

  • January 29, 2025

    4 Questions About Trump's Federal Worker Resignation Policy

    President Donald Trump’s offer of letting federal workers resign with several months of paid administrative leave raises questions about its legality and whether workers will actually get paid, attorneys said. Here, Law360 explores four questions that stem from the policy.

  • January 29, 2025

    White House Rescinds Trump's Spending Freeze

    The White House on Wednesday rescinded a directive freezing federal funding, saying it wants to end litigation and confusion, but said the move will not end a review of spending to ensure compliance with a series of executive orders by the president.

  • January 29, 2025

    RFK Jr. Disputes Anti-Vax Label In HHS Confirmation Hearing

    Robert F. Kennedy Jr. attempted Wednesday morning to convince Republican and Democratic lawmakers that he is not anti-vaccine, despite many of his past comments to the contrary, as he hopes to convince them to confirm his appointment as head of the U.S. Department of Health and Human Services.

  • January 28, 2025

    Trump Targets Gender-Affirming Care For Minors In New Order

    President Donald Trump ordered federal agencies late Tuesday to take steps to halt gender-affirming care for minors, including by cutting off Medicaid and military health coverage for what he called a "stain on our nation's history."

  • January 28, 2025

    Minn. AG Settles Novo Nordisk Insulin Claims With Price Cap

    Minnesota's attorney general has reached a settlement resolving a long-running lawsuit accusing Novo Nordisk of inflating insulin prices, with the company agreeing to a $35 per month cap on out-of-pocket costs for state residents.

  • January 28, 2025

    GSK Urges Del. Judge To Enhance $235M Skinny Label Win

    GlaxoSmithKline LLC is urging a Delaware federal judge to enhance the $235 million damages award a jury issued against Teva Pharmaceuticals USA Inc. in 2017, now that the dispute over skinny label infringement has returned to district court.

  • January 28, 2025

    Founder Can't Explain Hedge Fund's Filing Mismatch To Jury

    A hedge fund founder told a Denver jury Tuesday that he doesn't know why some of the fund's regulatory filings don't identify it as a director for a Colorado biopharmaceutical company, in a suit brought by stockholders who claim the fund must return $11 million earned from short-swing trades.

Expert Analysis

  • What To Expect Next From Federal Health Tech Regulation

    Author Photo

    Healthcare organizations should pay close attention to federal health information technology regulators' recent guidance concerning barriers to accessing electronic health information, which signals that more enforcement in this area is likely forthcoming, say attorneys at Ropes & Gray.

  • Trump Rollback Of Biden Enviro Policies: What To Expect

    Author Photo

    Donald Trump's upcoming second presidential term will usher significant shifts in U.S. environmental and natural resource law and policy — and while the Biden administration is racing to secure its legacy, the incoming Trump administration is making plans to dramatically roll back most, if not all, of Biden's environmental initiatives, say attorneys at Beveridge & Diamond.

  • Takeaways From State Votes On Abortion In The 2024 Election

    Author Photo

    Attorneys at Epstein Becker discuss how 10 states voted on ballot initiatives to either protect or restrict access to abortion in the 2024 general election, and analyze overarching trends.

  • Key Territory-Split Licensing Lessons For Life Sciences Cos.

    Author Photo

    Territory-split deals can allow life sciences companies to maximize products' potential across a range of geographic areas, but these deals also present unique challenges requiring highly bespoke structures that can make or break the value of an asset, say attorneys at Covington.

  • Legislation Most Likely To Pass In Lame Duck Session

    Author Photo

    As Congress begins its five-week post-election lame duck session, attorneys at Greenberg Traurig break down the legislative priorities and which proposals can be expected to pass.

  • Justices Must Weigh Reach Of Civil RICO In Cannabis Case

    Author Photo

    Oral arguments in Medical Marijuana Inc. v. Horn suggest that a majority of the U.S. Supreme Court may agree that a truck driver's losing his job after unknowingly ingesting THC and failing a drug test does not merit a racketeering claim — but the court may not buy the other side's theory of the case either, say attorneys at Lewis Baach.

  • Litigation Strategies In View Of New Double Patenting Rulings

    Author Photo

    Recent Federal Circuit decisions, including in Allergan v. MSN, raise several issues that patent owners should understand and consider addressing proactively regarding obviousness-type double patenting, at least in their prosecution strategies, say attorneys at Dentons.

  • Promoting Diversity In The Selection Of ADR Neutrals

    Excerpt from Practical Guidance
    Author Photo

    Choosing neutrals from diverse backgrounds is an important step in promoting inclusion in the legal profession, and it can enhance the legitimacy and public perception of alternative dispute resolution proceedings, say attorneys at Lowenstein Sandler.

  • Series

    Playing Ultimate Makes Us Better Lawyers

    Author Photo

    In addition to being fun, ultimate Frisbee has improved our legal careers by emphasizing the importance of professionalism, teamwork, perseverance, enthusiasm and vulnerability, say Arunabha Bhoumik and Adam Bernstein at Regeneron. 

  • E-Discovery Quarterly: Recent Rulings On Metadata

    Author Photo

    Several recent rulings reflect the competing considerations that arise when parties dispute the form of production for electronically stored information, underscoring that counsel must carefully consider how to produce and request reasonably usable data, say attorneys at Sidley.

  • Opinion

    PREVAIL Bill Is Another Misguided Attempt To Restrict PTAB

    Author Photo

    The decade-long campaign against the U.S. Patent and Trademark Office's Patent Trial and Appeal Board — currently focused on the PREVAIL Act that's slated for markup in the Senate — is not really about procedural issues, and it is not aimed at securing more accurate patentability decisions, says Clear IP's Joseph Matal, former acting director at the USPTO.

  • Striking A Balance Between AI Use And Attorney Well-Being

    Author Photo

    As the legal industry increasingly adopts generative artificial intelligence tools to boost efficiency, leaders must note the hidden costs of increased productivity, and work to protect attorneys’ well-being while unlocking AI’s full potential, says Ed Sohn at Factor.

  • Empathy In Mediation Offers A Soft Landing For Disputes

    Author Photo

    Experiencing a crash-landing on a recent flight underscored to me how much difference empathy makes in times of crisis or stress, including during mediation, says Eydith Kaufman at Alternative Resolution Centers.

  • Series

    Being An Artist Makes Me A Better Lawyer

    Author Photo

    My work as an artist has highlighted how using creativity and precision together — qualities that are equally essential in both art and law — not only improves outcomes, but also leads to more innovative and thoughtful work, says Sarah La Pearl at Segal McCambridge.

  • How Judiciary Can Minimize AI Risks In Secondary Sources

    Author Photo

    Because courts’ standing orders on generative artificial intelligence and other safeguards do not address the risk of hallucinations in secondary source materials, the judiciary should consider enlisting legal publishers and database hosts to protect against AI-generated inaccuracies, say attorneys at Lankler Siffert & Wohl.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.
Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!